PDF

Theranostics 2020; 10(26):11881-11891. doi:10.7150/thno.50598 This issue Cite

Research Paper

Correlation of multimodal ¹⁸F-DOPA PET and conventional MRI with treatment response and survival in children with diffuse intrinsic pontine gliomas

Giovanni Morana^1,2 , Domenico Tortora¹, Gianluca Bottoni³, Matteo Puntoni⁴, Gianluca Piatelli⁵, Federica Garibotto⁶, Salvina Barra⁷, Flavio Giannelli⁷, Angelina Cistaro³, Mariasavina Severino¹, Antonio Verrico⁶, Claudia Milanaccio⁶, Maura Massimino⁸, Maria Luisa Garrè⁶, Andrea Rossi¹, Arnoldo Piccardo³

1. Neuroradiology Unit, IRCCS Istituto Giannina Gaslini, Genova, Italy.
2. Department of Neurosciences, University of Turin, Turin, Italy.
3. Nuclear Medicine Unit, Ente Ospedaliero Ospedali Galliera, Genova, Italy.
4. Clinical Trial Unit, Scientific Directorate, Ente Ospedaliero Ospedali Galliera, Genoa, Italy.
5. Neurosurgery Unit, IRCCS Istituto Giannina Gaslini, Genova, Italy.
6. Neuro-oncology Unit, IRCCS Istituto Giannina Gaslini, Genova, Italy.
7. Department of Radiation Oncology, Ospedale Policlinico San Martino and University, Genova, Italy.
8. Pediatric Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.

✉ Corresponding author: Giovanni Morana, MD, PhD, Neuroradiology Unit, IRCCS Istituto Giannina Gaslini, via G. Gaslini 5 16147 Genova, Italy. Tel. (39) 010 56362516; Fax (39) 010 3779798; E-mail: giovanni.moranait; Orcid ID: http://orcid.org/0000-0001-8707-5969. More

Abstract

To evaluate the contribution of ¹⁸F-dihydroxyphenylalanine (DOPA) PET in association with conventional MRI in predicting treatment response and survival outcome of pediatric patients with diffuse intrinsic pontine gliomas (DIPGs).

Methods: We retrospectively analyzed 19 children with newly diagnosed DIPGs who underwent ¹⁸F-DOPA PET/CT and conventional MRI within one week of each other at admission and subsequent MRI follow-up. Following co-registration and fusion of PET and MRI, ¹⁸F-DOPA uptake avidity and extent (PET tumor volume and uniformity) at admission, along with MRI indices including presence of ring contrast-enhancement, tumor volume at admission and at maximum response following first-line treatment, were evaluated and correlated with overall survival (OS). The association between ¹⁸F-DOPA uptake tumor volume at admission and MRI tumor volume following treatment was evaluated. Statistics included Wilcoxon signed-rank and Mann-Whitney U tests, Kaplan-Meier OS curve and Cox analysis.

Results: DIPGs with a ¹⁸F-DOPA uptake Tumor/Striatum (T/S) ratio >1 presented an OS ≤ 12 months and lower degree of tumor volume reduction following treatment (p = 0.001). On multivariate analysis, T/S (p = 0.001), ring enhancement (p = 0.01) and the degree of MRI tumor volume reduction (p = 0.01) independently correlated with OS. In all patients, areas of increased ¹⁸F-DOPA uptake overlapped with regions demonstrating more prominent residual components/lack of response following treatment.

Conclusions: ¹⁸F-DOPA PET provides useful information for evaluating the metabolism of DIPGs. T/S ratio is an independent predictor of outcome. ¹⁸F-DOPA uptake extent delineates tumoral regions with a more aggressive biological behaviour, less sensitive to first line treatment.

Keywords: DOPA PET, MRI, Pediatric, DIPG, diffuse midline glioma

Introduction

In pediatric patients, diffuse intrinsic pontine glioma (DIPG) represents the most difficult brain tumor to treat and the leading cause of brain tumor-related death [1,2].

Despite recent remarkable genomic discoveries, partially included in the revised 2016 WHO classification, such as highly recurrent H3K27M histone mutations [3], there has been no significant progress in the management of DIPG. Radiotherapy (RT) remains the current standard of care, providing transient clinical improvement and a limited survival benefit. Tumor progression is almost universal, with median overall survival less than 1 year [4]. Several clinical trials over the last few decades have also investigated different adjuvant chemotherapies (ChT), albeit without significant survival benefit [4-6]. Routine biopsy in DIPG remains under debate [7] since the diagnosis may be established with imaging alone [8].

Several prior imaging studies focusing on conventional and/or advanced MRI modalities have attempted to identify non-invasive parameters able to predict survival at the time of diagnosis with not univocal results, most requiring further investigations in large DIPG clinical trials [9-14].

Additional non-invasive biomarkers that could predict disease evolution are still awaited to contribute to the establishment of well-timed, personalized and more effective therapies, aiming to improve overall survival and quality of life of DIPG patients.

Positron Emission Tomography (PET) imaging with amino-acid tracers, such as ¹⁸F-dihydroxyphenylalanine (DOPA), is a diagnostic tool able to provide non-invasive information of brain tumors. ¹⁸F-DOPA uptake has been demonstrated to correlate with aggressiveness of diffusely infiltrating pediatric gliomas [15-17] and with H3K27M mutational status, independently of histology [18]. The activity of ¹⁸F-DOPA PET seems both based on and strictly correlated to tumor metabolism, which is associated with enhanced and altered channeling of amino-acids for protein synthesis and cell division in pediatric high-grade infiltrative astrocytomas [19]. No prior studies have so far evaluated metabolic information obtained by ¹⁸F-DOPA PET focusing on DIPGs.

On the basis of these considerations, the overall objective of this retrospective study was to analyze diagnostic and prognostic information obtained by ¹⁸F-DOPA PET in a group of children with newly diagnosed DIPGs. Specifically, we aimed to evaluate the contribution of the ¹⁸F-DOPA PET delineated tumor volume at diagnosis to conventional MRI based tumor volume at diagnosis and at maximum response following first line ChT-RT treatment, and to correlate ¹⁸F-DOPA PET and MRI indices with outcome in terms of overall survival (OS).

Methods

Patient population

We retrospectively evaluated all consecutive pediatric patients (aged less than 18 years at diagnosis) referred at IRCCS Istituto Giannina Gaslini, Genoa, Italy between 2012 and 2019 for newly diagnosed treatment naïve DIPGs (T1 hypointense and T2 hyperintense diffusely infiltrating lesion arising and involving ≥ 50% of the pons) who underwent conventional MRI and ¹⁸F-DOPA PET at admission, and subsequent post-treatment MRI follow-up.

Nineteen (12 females and 7 males) subjects were identified. Patient age ranged from 3 to 10 years (median, 7 years). Six of these patients had been previously included in a retrospective study aimed to evaluate the diagnostic ability of ¹⁸F-DOPA PET and advanced MRI techniques in discriminating H3K27M-mutant from wild-type pediatric diffuse midline gliomas [18].

Clinical information reviewed for each subject included the time of diagnosis and treatment onset, OS (defined as the interval from treatment initiation to death from any cause), and treatments received. Because OS is regarded as the most reliable outcome variable for DIPG, progression-free survival was not evaluated [6].

Regarding treatment, all patients underwent first-line treatment with combined chemotherapy/immunotherapy (Vinorelbine and Nimotuzumab) and radiotherapy. Irradiation was performed in all patients using conventional fractionation (1.8 Gy per day) to a total dose of 54 Gy. In case of local progressive disease or progression with dissemination, re-irradiation was performed with variable doses and schedule according to disease sites (12 subjects underwent re-irradiation).

Ten patients underwent biopsy at diagnosis (following 18F-DOPA PET and MRI) with histological and molecular characterization. In particular, molecular analyses were performed to test the presence of mutations in the histone variants H3.3 (H3F3A) and H3.1 (HIST1H3B). Among subjects who underwent histological and molecular characterization, there were 2 patients with H3K27M wild-type (1 histologically defined diffuse astrocytoma and 1 anaplastic astrocytoma) and 8 with H3K27M-mutant lesions (4 histologically defined anaplastic astrocytomas and 4 glioblastomas). All subjects with H3K27M-mutant DIPGs presented mutations in the histone variant H3.3 (H3F3A).

Surveillance was performed with regular clinical and MRI follow-up. The Regional Ethics committee of Liguria, Genoa, Italy, approved the retrospective data evaluation.

Image protocol and analysis

Because the study spanned 7 years, MRI examinations were performed on 1.5T (14 patients; Intera Achieva; Philips, Best, the Netherlands) and 3T (5 patients; Ingenia Cx, Philips, Best, the Netherlands) scanners.

All patients underwent routine clinical MRI examinations including axial fluid attenuation inversion recovery (FLAIR), T2-weighted images, and pre- and post-contrast (0.1 mmol/kg, macrocyclic ionic agent) T1-weighted images.

¹⁸F-DOPA PET/CT was carried out at admission within one week of baseline MRI. Imaging studies were performed within 2 weeks before treatment initiation; subsequent evaluations were performed with MRI at 4-5 weeks after RT completion and then every 12-13 weeks, unless new symptoms occurred. In case of suspected pseudo-progression at first post-treatment MRI evaluation, additional close MRI follow-up at 4-5 weeks was performed (2 patients).

¹⁸F-DOPA PET studies were executed with a PET/CT Discovery ST system (GE Healthcare, Milwaukee, WI, USA), as previously described [17,18]. Data were acquired in 3-dimensional mode, 20 minutes after ¹⁸F-DOPA administration (median injected activity of 100 MBq, range 70-120 MBq according to body weight) with a scanning time of 30 minutes. Patients fasted for at least 4 hours before ¹⁸F-DOPA administration (IASOdopa®, IASON Labormedizine Ges. Mbh & Co. KG, Graz-Seiersberg, Austria). Carbidopa premedication was not utilized. A non-diagnostic low dose CT scan (120 kV, 80 mA, 0.6 s per rotation) was used for attenuation correction.

Images were first analysed on a dedicated workstation (Xeleris, GE Corporation), also allowing semiautomatic co-registration and fusion of ¹⁸F-DOPA PET and MR images to ensure precise anatomical comparability. Using dedicated software developed for research purposes (Quanta Oncology, Camelot Biomedical Systems, Genoa, Italy) we performed volumetric tumor analysis on axial ¹⁸F-DOPA PET and MRI FLAIR images. In detail, the anatomic tumor extent was delineated on MRI FLAIR images [20] using a perimeter technique with user-assisted semi-automated software; ¹⁸F-DOPA PET tumor volume was delineated based on ¹⁸F-DOPA uptake avidity (tumoral areas with increased uptake compared to normal background reference region). For each case tumor volume delineation was reviewed in consensus by a nuclear medicine physician and a neuroradiologist with 17 and 15 years of experience (A.P. and G.M.). Volume of interests (VOIs) were generated and ¹⁸F-DOPA PET and MRI tumor volume at admission were then recorded. The same procedure was performed following first-line treatment with ChT-RT on the MRI studies demonstrating the maximum degree of response (in all but two subjects the first MRI evaluation following ChT-RT was selected). MRI tumor volume following treatment and the corresponding tumor volume change since admission, were recorded.

For each patient, ¹⁸F-DOPA uniformity, defined as the percentage of the MRI tumor volume at admission (as delineated on FLAIR images) demonstrating increased ¹⁸F-DOPA PET uptake, was also calculated [21,22].

PET tumor volume was delineated on ¹⁸F-DOPA PET studies by including all voxels with standardized uptake value (SUV) above the maximum (max) SUV of the normal background reference tissue. For the normal (N) background reference tissue, a VOI (diameter 20 mm) was drawn in the normal cerebral hemisphere at the level of the left centrum semiovale, including cortical and white matter. For each case, the radiotracer concentration in the tumoral VOI was normalized to the injected dose per patient body weight, and the SUV max was obtained for each lesion [maximum pixel value (kBq/mL) within the VOI/injected dose (kBq)/patient weight (g)]. An additional VOI was drawn over the left striatum including the entire putamen (S). Ratios of tumor to normal tissue uptake were also generated by dividing the tumor SUVmax by the SUVmax of the striatum (T/S) [17,18]. In case of absence of increased ¹⁸F-DOPA uptake, a VOI including the tumor on MRI FLAIR images was delineated on co-registered ¹⁸F-DOPA PET images to generate T/S and T/N ratios.

Three main tumor uptake patterns were defined: (i) absence of increased ¹⁸F-DOPA uptake, characterized by a tumor uptake not exceeding the uptake of the normal background reference tissue (T/N ≤ 1) and lower uptake than striatum (T/S < 1); (ii) mildly/moderately increased ¹⁸F-DOPA uptake, characterized by a tumor uptake exceeding the uptake of the normal background reference tissue but remaining lower than or equal to that of the striatum (T/N > 1 and T/S ≤ 1); and (iii) markedly increased ¹⁸F-DOPA uptake, in which tumor uptake clearly exceeded that observed in the normal background reference tissue and striatum (T/N > 1 and T/S > 1) [23].

For each patient we also evaluated the association between baseline ¹⁸F-DOPA PET avidity and MRI based tumor volume at maximum response by delineating VOIs and assessing the overlap of the residual MRI tumor volume and initial ¹⁸F-DOPA PET volume [22].

Presence or absence of areas of ring-shaped enhancement on post-contrast T1-weighted images was also recorded. Distribution of areas of ring-shaped enhancement in relation to areas of increased ¹⁸F-DOPA uptake was also evaluated on baseline MRI studies.

Risk stratification

Each patient was risk stratified according to age, sex, H3K27M mutation, presence or absence of ring-shaped enhancement on MRI, pre- and post-treatment MRI tumor volume, 18F-DOPA uptake avidity (T/S), pre-treatment PET tumor volume and pre-treatment PET uniformity.

Statistical analysis

Descriptive statistics included mean, standard deviation, minimum, and maximum of continuous factors and scores; in the case of categorical factors, number and percentage distribution were used.

Due to the non-normality of data (graphically checked), the Wilcoxon signed-rank test was used to evaluate pre- versus post-first line treatment changes among variables of interest, whereas the Mann-Whitney U tests was applied to compare MRI tumor volume changes after treatment between patients with and without increased ¹⁸F-DOPA uptake.

Kaplan-Meier estimates of the cumulative probability of OS at 12 months were performed and log-rank test was adopted to test differences between groups (log-rank test for trend in case of 3 or more ordinal groups). T/S was evaluated as a dichotomous variable (≤1 and >1) in the Kaplan-Meyer analysis. The Cox proportional hazard model was used to estimate the risk of death from any cause after adjustment for age and sex. Only the covariates that were significant at the p < 0.05 level in the univariate analysis (where we examined all risk factors included in our study), were entered into the multivariate analysis. The proportional hazard assumption was graphically checked. Since the parameters were highly correlated, to avoid collinearity, we used different models for each parameter to test their independent association with OS. We adopted 1/Variance Inflation Factor (VIF) as a measure of collinearity. Two-tailed probabilities were reported, and a p value of 0.05 was used to define nominal statistical significance; given the explorative nature of the study, no multiple testing corrections were applied. All analyses were conducted using Stata (version 13, Stata-Corp) software.

Results

Diagnostic evaluation and correlation with tumor response

Demographic data, histological and molecular diagnosis, MRI findings (ring enhancement, pre- and post-treatment MRI tumor volumes), ¹⁸F-DOPA uptake avidity and extent (PET tumor volume and uniformity), and survival of all patients are summarized in Table 1. A detailed report of all patients is provided in Table S1.

On baseline MRI, areas of ring-shaped enhancement were present in 6 DIPGs (31.6%). Three of these lesions were glioblastomas, H3K27M-mutant. The remaining 5 patients with H3K27M-mutant and the 2 patients with H3K27M wild-type DIPGs did not show areas of ring enhancement.

On ¹⁸F-DOPA PET imaging, 4 tumors (21%) showed absence of increased tracer uptake. Of these, two underwent biopsy and turned out to be H3K27M wild-type. Two DIPGs presented mildly/moderately increased tracer uptake (10.5%), whereas the remaining 13 lesions (68.5%) exhibited markedly increased uptake. All subjects with H3K27M-mutant DIPGs presented markedly increased tracer uptake (median T/S ratio: 1.49, range: 1.10-2.32). All subjects with ring-shaped enhancement on post-contrast T1-weighted images presented also markedly increased uptake. In detail, all areas of ring-shaped enhancement corresponded to regions with markedly increase uptake; however, markedly increase uptake extended beyond these areas in 5 out of 6 subjects.

No lesions presented ¹⁸F-DOPA PET tumor volumes larger than MRI defined tumor volumes or uptake extending beyond MRI defined tumor margins.

Following first line ChT-RT, MRI tumor volumes at maximum response were lower than pre-treatment tumor volumes (median 20 cc vs 27.64 cc, p < 0.001).

Patients with absence of increased tracer uptake and the 2 patients with mildly/moderately increase uptake (T/S ≤ 1) demonstrated higher median degree of MRI tumor volume reduction compared to subjects with markedly increased tracer uptake (T/S >1) (23.5 cc versus 5.52 cc; p = 0.001).

When evaluating the association between ¹⁸F-DOPA uptake tumor volume at admission with the MRI tumor volume at maximum response, areas of increased tracer uptake corresponded to regions with more prominent residual components/lack of response following treatment in all patients. Representative images of DIPGs at admission and following first-line ChT-RT are reported in Figures 1 and 2.

Prognostic evaluation

The median OS of the whole cohort was 10 months (range 5-38 months) and cumulative probability of survival (OS) at 12 months was 32% (95% confidence interval [CI]: 13% - 52%).

 Figure 1 

Co-registered and fused MRI and ¹⁸F-DOPA PET images of DIPGs with T/S ≤ 1. First row: 8-year-old male. Pre-treatment contrast-enhanced (CE) T1-weighted imaging did not show contrast enhancement. MRI tumor volume (as delineated on FLAIR images) was 31.46 cc. ¹⁸F-DOPA PET and fused ¹⁸F-DOPA PET/MRI revealed absence of increased tracer uptake within the lesion (T/S 0.44). Post-treatment FLAIR at maximum response demonstrated an MRI tumor volume of 7 cc. Overall survival (OS) was 27 months. Second row: 7-year-old male (diffuse astrocytoma, H3K27M wild-type). Pre-treatment CE T1-weighted imaging did not reveal areas of contrast enhancement. MRI tumor volume was 45 cc. ¹⁸F-DOPA PET and fused ¹⁸F-DOPA PET/MRI revealed absence of increased tracer uptake (T/S 0.45). On post-treatment FLAIR the MRI tumor volume was 16 cc. OS was 38 months. Third row: 7-year-old female. Pre-treatment CE T1-weighted imaging showed lack of contrast enhancement. MRI tumor volume was 25.06 cc. PET images revealed absence of increased tracer uptake in the vast majority of the lesion with small areas of mildly-moderately increased uptake (T/S 0.7). PET tumor volume was 4 cc, corresponding to a uniformity of 15.96%. Post-treatment FLAIR showed an MRI tumor volume of 8.35 cc. Notice the degree of overlap between more prominent residual components on FLAIR and increased ¹⁸F-DOPA uptake. OS was 16 months. Fourth row: 5-year-old female. Pre-treatment CE T1-weighted imaging did not show contrast enhancement. MRI tumor volume was 25.03 cc. ¹⁸F-DOPA PET and fused ¹⁸F-DOPA PET/MRI revealed mildly-moderately increased uptake (T/S 0.93) within the left ventrolateral component of the lesion (PET tumor volume: 8 cc, uniformity: 31.96%) corresponding to the most prominent residual component following treatment. Post-treatment FLAIR demonstrated an MRI tumor volume of 11.27 cc. OS was 28 months.

 Figure 2 

Co-registered and fused MRI and ¹⁸F-DOPA PET images of DIPGs with T/S > 1. First row: 4-year-old female. Pre-treatment contrast-enhanced (CE) T1-weighted imaging showed ring enhancement. MRI tumor volume was 40 cc. ¹⁸F-DOPA PET and fused ¹⁸F-DOPA PET/MRI revealed markedly increased uptake (T/S 1.09) with a PET tumor volume of 21 cc, corresponding to a uniformity of 52.5%. Post-treatment FLAIR demonstrated an MRI tumor volume of 28.9 cc. Overall survival (OS) was 9 months. Notice the coincidence between the tumoral component with increased uptake and the residual lesion, and the tumor volume reduction in the left ventrolateral pons corresponding to absence of increased uptake. Second row: 7-year-old male (anaplastic astrocytoma, H3K27M-mutant). Pre-treatment CE T1-weighted imaging did not reveal areas of ring enhancement. MRI tumor volume was 34.06 cc. On ¹⁸F-DOPA PET and fused ¹⁸F-DOPA PET/MRI the T/S was 1.27, the tumor volume 25 cc, and the uniformity 73.39%. Following treatment, the MRI tumor volume was of 33.7 cc. OS was 10 months. Third row: 10-year-old female. On pre-treatment CE T1-weighted imaging there was extensive ring enhancement. MRI tumor volume was 26 cc. On ¹⁸F-DOPA PET and fused ¹⁸F-DOPA PET/MRI the lesion presented a T/S of 1.7 and a tumor volume of 18 cc, corresponding to a uniformity of 69.23%. Post-treatment FLAIR image demonstrated an MRI tumor volume of 20 cc. OS was 6 months. Fourth row: 10-year-old male (glioblastoma, H3K27M-mutant). Pre-treatment CE T1-weighted imaging revealed a right focal area of ring enhancement. MRI tumor volume was 46 cc. ¹⁸F-DOPA PET and fused ¹⁸F-DOPA PET/MRI demonstrated markedly increased uptake (T/S 2.32) and a tumor volume of 31 cc, corresponding to a uniformity of 67.39%. Following treatment, the MRI tumor volume was 42 cc. OS was 6 months.

Figure 3 shows Kaplan-Meier OS curves for all the main risk factors analyzed in our study. Subjects with T/S ratios > 1 (markedly increased uptake) had a significantly higher risk of death (p = 0.0001, Figure 3A) than those with T/S ≤ 1. At the same time, we found that at univariate level, H3K27M-mutant lesions and patients with ring enhancement on post-contrast T1-weighted images had a significantly lower survival (hazard ratio [HR] = 3.51, 95% CI: 1.11-11.1, p = 0.024, not shown, and HR = 3.91, 95% CI: 1.17-13.1, p = 0.011, Figure 3B). Patients with larger MRI tumor volumes at admission did not show lower survival (p = 0.738, Figure 3C). By contrast, post-treatment MRI tumor volume at maximum response and tumor volume reduction following treatment were significantly correlated with OS (p = 0.012, Figure 3D, and p = 0.005, Figure 3E). Median age and gender were not correlated with OS (p = 0.608, not shown), whereas patients with greater ¹⁸F-DOPA PET tumor volume (> 21 cc vs. < 7 cc: HR = 5.74, 95% CI: 1.46-22.62; 7-21 cc vs. < 7 cc: HR = 2.31, 95% CI: 0.73-7.34, p = 0.004, Figure 3F) and uniformity (p = 0.001, not shown) were at higher risk of death. However, when we adjusted risk estimates for age and gender by using a multivariate Cox model, including only the covariates with a significant association on univariate analysis, only T/S (HR = 55.50, 95% CI: 5.3-580.3, p = 0.001), ring enhancement (HR 12.4, 95% CI: 1.8-83.1, p = 0.01) and MRI tumor volume reduction following treatment (HR 0.1, 95% CI: 0.02-0.56, p = 0.01) resulted to be significant predictors of OS. A trend emerged for age (p = 0.061) (Table 2).

 Figure 3 

Kaplan-Meier plots of overall survival (OS) according to T/S (A), ring enhancement (B), pre-treatment MRI tumor volume (C), post-treatment MRI tumor volume at maximum response (D), degree of MRI tumor volume reduction (E), and pre-treatment ¹⁸F-DOPA PET tumor volume (F). ¹⁸F-DOPA PET and MRI (based on FLAIR images) tumor volume measurements were categorized considering tertiles of each distribution.

Discussion

The aim of this study was to evaluate and correlate ¹⁸F-DOPA uptake intensity and extent (PET tumor volume and uniformity) with conventional MRI indices, and with treatment response and survival of pediatric patients with DIPGs. To the best of our knowledge, no prior studies have so far evaluated the role of ¹⁸F-DOPA PET on a selected population of children with DIPGs. Overall, a limited number of studies have assessed PET imaging in DIPGs [21,22,24-27].

Zukotynski et al. [21] analyzed the role of ¹⁸F-fluorodeoxyglucose (FDG) PET in patients with newly diagnosed DIPGs and observed that the intensity of FDG uptake did not correlate with outcome; however, in patients with ¹⁸F-FDG PET uptake involving more than half of the tumor, survival appeared to be decreased. A more recent study from the same group [24] evaluated ¹⁸F-FDG histogram metrics in children with DIPGs, revealing that parameters such as skewness or kurtosis did not show a significant association with outcome.

An additional multimodal study with ¹⁸F-FDG PET performed by Goda et al. [25] did not find a significant correlation between baseline DIPGs ¹⁸F-FDG uptake and survival, even though patients with increased PET uptake had a lower 1-year OS (40%) and PFS (33%) compared to patients with lower uptake (66.7% and 40%, respectively).

Of note, among amino-acid PET tracers, only three prior pediatric research studies, all performed with ¹¹C-Methionine (MET), have been performed [22,26,27]. Two of these studies evaluated both ¹⁸F- FDG and ¹¹C-MET to characterize the tumoral metabolic activity. In particular, Pirotte et al. [26] investigated a group of children with different infiltrating brainstem tumors highlighting the role of PET imaging to biopsy planning and target selection. Rosenfeld et al. [27], a few years later, found that patients with the shortest survival time were those who had ¹⁸F-FDG negative and ¹¹C-MET positive scans, whereas patients with the longest survival times were those with both negative ¹⁸F-FDG and ¹¹C-MET scans suggesting a trend toward improved survival, even though the correlation was not statistically significant.

A very recent study performed by Tinkle et al. [22] evaluated the role of ¹¹C-MET PET in 22 subjects with typical and atypical DIPGs, treated with RT using conventional fractionation (1.8Gy per day) to a total dose of 54‐55.8Gy; although baseline ¹¹C-MET PET intensity and uniformity metrics did not correlate with survival outcomes, initial ¹¹C-MET avidity overlapped with recurrent tumor in 100% of cases, delineating regions at increased risk for recurrence. These authors also suggested to explore the role of ¹⁸F-DOPA in this pediatric tumor subtype.

In the present study, a significant relationship between ¹⁸F-DOPA uptake avidity and extent (¹⁸F-DOPA tumor volume and uniformity) was found in terms of OS on univariate analysis, and the ¹⁸F-DOPA PET metric T/S was an independent predictor of survival on multivariate analysis. Of note, all DIPGs with a T/S ratio >1 (markedly increase tracer uptake) presented an OS ≤ 12 months. As demonstrated in prior studies [16-18,23], T/S ratio is an extremely helpful ¹⁸F-DOPA PET parameter to predict pediatric diffuse astrocytic tumor behavior in a clinical diagnostic setting; moreover, ¹⁸F-DOPA uptake in the striatum allows to further stratify tumor uptake ratios when compared to other amino-acid PET tracers. Of note, even though striatal ¹⁸F-DOPA uptake may be subject to changes related to age in adults [28,29], we believe that in our pediatric population (children aged 3 to 10 years) the impact of age-related striatal uptake does not appear to be significant.

As previously reported in a large DIPG study [4], also in our current research the presence of ring enhancement on MRI proved to be an additional independent predictor of adverse OS. Of note, when considering our population, only 6 DIPGs presented this MRI finding while, among the remaining 13 subjects without ring enhancement, 7 additional patients presented an OS ≤ 12 months. Overall, among subjects with an OS ≤ 12 months, 46% presented ring enhancement whereas 100% presented a T/S ratio >1. Regarding the relationship between ¹⁸F-DOPA accumulation and areas of contrast-enhancement, in all but one subjects markedly increase uptake extended beyond these areas, and was present in additional seven subjects without any area of contrast-enhancement, thus providing additional non-invasive diagnostic information in keeping with prior studies [15,16,30].

Tumor volume reduction following therapy (difference between MRI tumor volume at admission and at maximum response following first line treatment) also correlated significantly with OS on multivariate analysis. This result is in line with a prior study demonstrating that patients with more substantial tumor volume decrease following therapy had better OS [20]. Differently from the above-mentioned study, MRI tumor volume at admission did not show a significant correlation with outcome.

When compared to MRI tumor volume decrease, the main potential advantage of ¹⁸F-DOPA PET T/S ratio or presence of ring enhancement consists in the possibility of obtaining prognostic information at admission and not following treatment.

When compared to the amino-acid PET tracer ¹¹C-MET, which did not show a correlation between uptake and outcome [22], our findings suggest that in DIPGs ¹⁸F-DOPA uptake might be related to additional mechanisms, such as expression of supplementary amino-acid transporters, as demonstrated in a prior study where ¹⁸F-DOPA uptake values of brain gliomas were not exclusively dependent on L-type amino-acid transporter (LAT) 1 expression [31,32]. In adult diffuse gliomas has been suggested that an apparent discrepancy between the uptake patterns of ¹¹C-MET and ¹⁸F-DOPA may be linked to the metabolomic profile of IDH-mutated tumors [33]. Since pediatric diffusely infiltrating astrocytic tumors typically do not present IDH mutation different mechanisms should be considered. In a current ongoing unpublished research, our preliminary findings show that the glutamine transporter sodium-coupled neutral amino-acid transporter (SNAT) 1 (Slc38a1) is involved in ¹⁸F-DOPA uptake of cell lines of pediatric high-grade gliomas, in addition to LAT1. Further studies are needed to evaluate and elucidate the potential role of glutamine for DIPGs survival and proliferation. Glutamine addiction in adult high-grade gliomas is well known [34].

In a recent study we also demonstrated that anaplastic astrocytomas and glioblastomas H3K27M-mutant arising in midline brain structures had a significant higher uptake than wild-type midline high-grade gliomas [18]. H3K27M-mutant diffuse midline gliomas, which include about 85% of DIPGs, have been reported to exhibit elevated expression and dependency on dopamine receptor (DR) D2 [35]. DRD2 is a G protein-coupled receptor that promotes tumor growth. A recent study also demonstrated that glioblastoma cells (including tumor samples from patients) can synthesize and secrete dopamine, suggesting an autocrine signaling process and an underlying role for dopamine in gliomagenesis [36]. DOPA is a precursor for dopamine synthesis, and when compared to other amino-acid PET tracers ¹⁸F-DOPA uptake might be more specifically related to cells that synthesize and secrete dopamine.

In the study performed by Tinkle et al. [22] ¹¹C-MET PET-delineated tumor extended beyond the T2-FLAIR abnormality in most patients at diagnosis. This is in distinction to our findings where ¹⁸F-DOPA PET-delineated tumor was always confined within the MRI tumor volume. However, when comparing the association between pre-treatment ¹⁸F-DOPA PET tumor volume and post-treatment MRI tumor volume, areas of increased ¹⁸F-DOPA uptake corresponded to regions with more prominent residual components/lack of response in all patients. This finding is in line with the above-mentioned study [22] demonstrating a correlation between the location of increased ¹¹C-MET uptake at admission and the subsequent region of local tumor progression.

Considering the significant association between ¹⁸F-DOPA uptake avidity and extent with outcome, our findings indicate that tumoral areas with increased tracer uptake show a more aggressive biological behavior, with reduced sensitivity to ChT-RT.

In the era of precision medicine, the results of the present study could delineate subcategories of patients who might benefit from personalized management strategies.

Given the lack of current medical therapies able to significantly impact outcome and the known feasibility of re-irradiation for recurrent DIPGs [37,38], a more personalized RT treatment might be tested on the basis of the metabolic characteristics of the lesion; such an approach might also be considered as selection criteria in discriminating DIPGs that may better benefit re-irradiation, since not all DIPGs improve prognosis with re-RT, as reported in a recent meta-analysis [37].

In addition, patients with lack of increased ¹⁸F‐DOPA uptake or with mild-moderate uptake (which correlate with higher tumor volume response degree and better outcome) might be selected to perform a first radiotherapy course with lower dose than 54 Gy at admission, in order to give them the possibility of multiple radiotherapy courses. A current clinical trial (NCT03620032; clinicaltrials.gov) is actively investigating multiple elective RT courses in DIPGs.

The role of ¹⁸F-DOPA PET might also be evaluated on follow-up studies to assess treatment response. A prior study performed in adult patients with recurrent high-grade malignant gliomas on antiangiogenic treatment demonstrated the powerful role of ¹⁸F-DOPA PET in assessing treatment response and for providing prognostic information [39].

Our results should be interpreted with awareness of some limitations. This is a retrospective study in which a limited number of patients was evaluated; however, we included only pediatric patients with DIPGs studied with ¹⁸F-DOPA PET, and currently our cohort constitutes to the best of our knowledge the first and largest series of DIPGs evaluated with this technique so far. We acknowledge that only 10 out of 19 subjects underwent biopsy, thus limiting the molecular characterization of the entire cohort. However, the aim of the present study was to evaluate the degree of correlation between ¹⁸F-DOPA PET avidity and extent with outcome, and molecular characterization of DIPG did not influence the treatment regimen which was homogeneous among subjects. In the current study we evaluated only static ¹⁸F-DOPA PET parameters; as highlighted in a recent research on adult gliomas [40], dynamic ¹⁸F-DOPA PET analysis in pediatric gliomas might provide additional information in future investigations. Furthermore, in this study we did not compare ¹⁸F-DOPA PET with advanced MR imaging modalities; as highlighted in a recent study which demonstrated a significant association of different advanced MR imaging metrics with survival [41], prospective clinical trials should be performed in order to evaluate the synergic role of these techniques. We recognize that in the current study we did not evaluate the prognostic role of T/N, even though we used this parameter to stratify tumor uptake patterns and to delineate tumor volume. However, in pediatric diffusely infiltrating astrocytic tumors, according to our experience, the T/N ratio did not provide additional information when compared to T/S, in terms of differentiation between low-grade and high-grade lesions and with regard to outcome prediction [17,23]; of note, in pediatric diffuse midline gliomas, which according to the revised 2016 World Health Organization classification of tumors of the central nervous system include DIPGs, T/S was the only parameter able to discriminate H3K27M-mutant from wild-type tumors, independently of histology [18]. Furthermore, as reported by the Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino-acids [42], the striatum is the only recommended reference region for semiquantitative measures of ¹⁸F-DOPA PET activity. However, regarding cut-off thresholds for definition of biological tumor volume the EANM/RANO/EANO and SNMMI guidelines indicate for ¹⁸F-DOPA a standardized uptake value (SUV) higher than the mean SUV in healthy striatum [39,42]. Since it is acknowledged that this cut-off value lacks histological validation [42], and according to Cicone et al. [43], we used a different threshold. Of note, since when compared to their adult counterparts, pediatric astrocytic tumors are considered biologically distinct entities [44], and in light of the complex physiological changes occurring in the brain during development, especially in the first two years of life (i.e., cortical organization, white matter myelination, changes in cerebral blood flow), current adults guidelines and ¹⁸F-DOPA PET literature based on adult gliomas may not be entirely applicable to pediatric gliomas, especially in the era of precision medicine.

Conclusions

¹⁸F-DOPA PET imaging provides useful non-invasive information for evaluating the metabolism of DIPGs. Our results demonstrate that the ¹⁸F-DOPA PET metric T/S is an independent predictor of overall survival. ¹⁸F-DOPA uptake extent corresponds to tumoral components with a more aggressive biological behaviour, less sensitive to first line ChT-RT. Larger prospective studies are needed to evaluate whether ¹⁸F-DOPA PET can provide additional information for more personalized management schemes.

Abbreviations

PET: positron emission tomography; MRI: magnetic resonance imaging; DOPA: dihydroxyphenylalanine; DIPG: diffuse intrinsic pontine glioma; OS: overall survival; T/S: tumor/striatum; RT: radiotherapy; ChT: chemotherapy; FLAIR: fluid attenuation inversion recovery; CT: computed tomography; FDG: fluorodeoxyglucose; MET: methionine; LAT: L-type amino acid transporter; SNAT: sodium-coupled neutral amino acid transporter; DR: dopamine receptor.

Supplementary Material

Supplementary table S1.

Acknowledgements

This work was supported, in part, by the Associazione Italiana per la Ricerca dei Tumori Cerebrali del Bambino (ARTUCEBA).

Competing Interests

The authors have declared that no competing interest exists.

References

1. Buczkowicz P, Bartels U, Bouffet E, Becher O, Hawkins C. Histopathological spectrum of paediatric diffuse intrinsic pontine glioma: diagnostic and therapeutic implications. Acta Neuropathol. 2014;128:573-81

2. Robison NJ, Kieran MW. Diffuse intrinsic pontine glioma: a reassessment. J Neurooncol. 2014;119:7-15

3. Wu G, Diaz AK, Paugh BS, Rankin SL, Ju B, Li Y. et al. The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma. Nat Genet. 2014;46:444-50

4. Jansen MH, Veldhuijzen van Zanten SE, Sanchez Aliaga E, Heymans MW, Warmuth-Metz M, Hargrave D. et al. Survival prediction model of children with diffuse intrinsic pontine glioma based on clinical and radiological criteria. Neuro Oncol. 2015;17:160-166

5. Castel D, Philippe C, Calmon R, Le Dret L, Truffaux N, Boddaert N. et al. Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes. Acta Neuropathol. 2015;130:815-827

6. Hoffman LM, Veldhuijzen van Zanten SEM, Colditz N, Colditz N, Baugh J, Chaney B, Hoffmann M. et al. Clinical, Radiologic, Pathologic, and Molecular Characteristics of Long-Term Survivors of Diffuse Intrinsic Pontine Glioma (DIPG): A Collaborative Report From the International and European Society for Pediatric Oncology DIPG Registries. J Clin Oncol. 2018;36:1963-1972

7. Tejada S, Aquilina K, Goodden J, Pettorini B, Mallucci C, van Veelen ML, Thomale UW. Biopsy in diffuse pontine gliomas: expert neurosurgeon opinion-a survey from the SIOPE brain tumor group. Childs Nerv Syst. 2020;36:705-711

8. Cooney TM, Cohen KJ, Guimaraes CV, Dhall G, Leach J, Massimino M. et al. Response assessment in diffuse intrinsic pontine glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group. Lancet Oncol. 2020;21:e330-e336

9. Lober RM, Cho Y-J, Tang Y, Barnes PD, Edwards MS, Vogel H. et al. Diffusion weighted MRI derived apparent diffusion coefficient identifies prognostically distinct subgroups of pediatric diffuse intrinsic pontine glioma. J Neurooncol. 2014;117:175-82

10. Steffen-Smith EA, Shih JH, Hipp SJ, Bent R, Warren KE. Proton magnetic resonance spectroscopy predicts survival in children with diffuse intrinsic pontine glioma. J Neurooncol. 2011;105:365-73

11. Hipp SJ, Steffen-Smith E, Hammoud D, Shih JH, Bent R, Warren KE. Predicting outcome of children with diffuse intrinsic pontine gliomas using multiparametric imaging. Neuro Oncol. 2011;13:904-9

12. Poussaint TY, Vajapeyam S, Ricci KI, Panigrahy A, Kocak M, Kun LE. et al. Apparent diffusion coefficient histogram metrics correlate with survival in diffuse intrinsic pontine glioma: a report from the Pediatric Brain Tumor Consortium. Neuro Oncol. 2016;18:725-34

13. Liu AK, Brandon J, Foreman NK, Fenton LZ. Conventional MRI at presentation does not predict clinical response to radiation therapy in children with diffuse pontine glioma. Pediatr Radiol. 2009;39:1317-20

14. Hargrave D, Chuang N, Bouffet E. Conventional MRI cannot predict survival in childhood diffuse intrinsic pontine glioma. J Neurooncol. 2008;86:313-9

15. Morana G, Piccardo A, Garrè ML, Nozza P, Consales A, Rossi A. Multimodal magnetic resonance imaging and 18F-L-dihydroxyphenylalanine positron emission tomography in early characterization of pseudoresponse and nonenhancing tumor progression in a pediatric patient with malignant transformation of ganglioglioma treated with bevacizumab. J Clin Oncol. 2013;31:e1-5

16. Morana G, Piccardo A, Puntoni M, Nozza P, Cama A, Raso A. et al. Diagnostic and prognostic value of 18F-DOPA PET and 1H-MR spectroscopy in pediatric supratentorial infiltrative gliomas: a comparative study. Neuro Oncol. 2015;17:1637-47

17. Morana G, Piccardo A, Tortora D, Puntoni M, Severino M, Nozza P. et al. Grading and outcome prediction of pediatric diffuse astrocytic tumors with diffusion and arterial spin labeling perfusion MRI in comparison with 18F-DOPA PET. Eur J Nucl Med Mol Imaging. 2017;44:2084-93

18. Piccardo A, Tortora D, Mascelli S, Severino M, Piatelli G, Consales A. et al. Advanced MR imaging and 18F-DOPA PET characteristics of H3K27M-mutant and wild-type pediatric diffuse midline gliomas. Eur J Nucl Med Mol Imaging. 2019;46:1685-1694

19. Heiss WD, Raab P, Lanfermann H. Multimodality assessment of brain tumors and tumor recurrence. J Nucl Med. 2011;52:1585-600

20. Poussaint TY, Kocak M, Vajapeyam S, Packer RI, Robertson RL, Geyer R. et al. MRI as a central component of clinical trials analysis in brainstem glioma: a report from the Pediatric Brain Tumor Consortium (PBTC). Neuro Oncol. 2011;13:417-427

21. Zukotynski KA, Fahey FH, Kocak M, Alavi A, Wong TZ, Treves ST. et al. Evaluation of 18F-FDG PET and MRI associations in pediatric diffuse intrinsic brain stem glioma: a report from the Pediatric Brain Tumor Consortium. J Nucl Med. 2011;52:188-95

22. Tinkle CL, Duncan EC, Doubrovin M, Han Y, Li Y, Kim H. et al. Evaluation of 11C-Methionine PET and Anatomic MRI Associations in Diffuse Intrinsic Pontine Glioma. J Nucl Med. 2019;60:312-319

23. Morana G, Piccardo A, Milanaccio C, Puntoni M, Nozza P, Cama A. et al. Value of 18F-3,4-dihydroxyphenylalanine PET/MR image fusion in pediatric supratentorial infiltrative astrocytomas: a prospective pilot study. J Nucl Med. 2014;55:718-23

24. Zukotynski KA, Vajapeyam S, Fahey FH, Kocak M, Brown D, Ricci KI. et al. Correlation of 18F-FDG PET and MRI Apparent Diffusion Coefficient Histogram Metrics with Survival in Diffuse Intrinsic Pontine Glioma: A Report from the Pediatric Brain Tumor Consortium. J Nucl Med. 2017;58:1264-1269

25. Goda JS, Dutta D, Raut N, Juvekar SL, Purandare N, Rangarajan V. et al. Can multiparametric MRI and FDG-PET predict outcome in diffuse brainstem glioma? A report from a prospective phase-II study. Pediatr Neurosurg. 2013;49:274-81

26. Pirotte BJ, Lubansu A, Massager N, Wikler D, Goldman S, Levivier M. Results of positron emission tomography guidance and reassessment of the utility of and indications for stereotactic biopsy in children with infiltrative brainstem tumors. J Neurosurg. 2007;107:392-9

27. Rosenfeld A, Etzl M, Bandy D, Carpenteri D, Gieseking A, Dvorchik I, Kaplan A. Use of positron emission tomography in the evaluation of diffuse intrinsic brainstem gliomas in children. J Pediatr Hematol Oncol. 2011;33:369-73

28. De La Fuente-Fernández R, Lim AS, Sossi V, Adam MJ, Ruth TJ, Calne DB. et al. Age and severity of nigrostriatal damage at onset of Parkinson's disease. Synapse. 2003;47:152-8

29. Carideo L, Minniti G, Mamede M, Scaringi C, Russo I, Scopinaro F, Cicone F. 18F-DOPA uptake parameters in glioma: effects of patients' characteristics and prior treatment history. Br J Radiol. 2018;91:20170847

30. Pafundi DH, Laack NN, Youland RS, Parney IF, Lowe VJ, Giannini C. et al. Biopsy validation of 18F-DOPA PET and biodistribution in gliomas for neurosurgical planning and radiotherapy target delineation: results of a prospective pilot study. Neuro Oncol. 2013;15:1058-67

31. Dadone-Montaudié B, Ambrosetti D, Dufour M, Darcourt J, Almairac F, Coyne J. et al. [18F] FDOPA standardized uptake values of brain tumors are not exclusively dependent on LAT1 expression. PLoS One. 2017;12:e0184625

32. Youland RS, Kitange GJ, Peterson TE, Pafundi DH, Ramiscal JA, Pokorny JL. et al. The role of LAT1 in (18)F-DOPA uptake in malignant gliomas. J Neurooncol. 2013;111:11-8

33. Verger A, Taieb D, Guedj E. Is the information provided by amino acid PET radiopharmaceuticals clinically equivalent in gliomas? Eur J Nucl Med Mol Imaging. 2017;44:1408-1410

34. Obara-Michlewska M, Szeliga M. Targeting Glutamine Addiction in Gliomas. Cancers (Basel). 2020;12(2E pii):310

35. Chi AS, Tarapore RS, Hall MD, Shonka N, Gardner S, Umemura Y. et al. Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201. J Neurooncol. 2019;145:97-105

36. Caragher SP, Shireman JM, Huang M, Miska J, Atashi F, Baisiwala S. et al. Activation of Dopamine Receptor 2 Prompts Transcriptomic and Metabolic Plasticity in Glioblastoma. J Neurosci. 2019;39:1982-1993

37. Lu VM, Welby JP, Mahajan A, Laack NN, Daniels DJ. Reirradiation for diffuse intrinsic pontine glioma: a systematic review and meta-analysis. Childs Nerv Syst. 2019;35:739-746

38. Massimino M, Biassoni V, Miceli R, Schiavello E, Warmuth-Metz M, Modena P. et al. Results of nimotuzumab and vinorelbine, radiation and re-irradiation for diffuse pontine glioma in childhood. J Neuro-Oncol. 2014;118:305-312

39. Schwarzenberg J, Czernin J, Cloughesy TF, Ellingson BM, Pope WB, Grogan T. et al. Treatment response evaluation using 18F-FDOPA PET in patients with recurrent malignant glioma on bevacizumab therapy. Clin Cancer Res. 2014;20:3550-9

40. Ginet M, Zaragori T, Marie PY, Roch V, Gauchotte G, Rech F. et al. Integration of dynamic parameters in the analysis of 18F-FDopa PET imaging improves the prediction of molecular features of gliomas. Eur J Nucl Med Mol Imaging. 2020;47:1381-1390

41. Vajapeyam S, Brown D, Billups C, Patay Z, Vezina G, Shiroishi MS. et al. Advanced ADC Histogram, Perfusion, and Permeability Metrics Show an Association with Survival and Pseudoprogression in Newly Diagnosed Diffuse Intrinsic Pontine Glioma: A Report from the Pediatric Brain Tumor Consortium. AJNR Am J Neuroradiol. 2020;41:718-724

42. Law I, Albert NL, Arbizu J, Boellaard R, Drzezga A, Galldiks N. et al. Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [18F]FDG: version 1.0. Eur J Nucl Med Mol Imaging. 2019;46:540-557

43. Cicone F, Carideo L, Minniti G, Scopinaro F. The mean striatal 18F-DOPA uptake is not a reliable cut-off threshold for biological tumour volume definition of glioma. Eur J Nucl Med Mol Imaging. 2019;46:1051-1053

44. Morana G, Tortora D, Staglianò S, Nozza P, Mascelli S, Severino M. et al. Pediatric astrocytic tumor grading: comparison between arterial spin labeling and dynamic susceptibility contrast MRI perfusion. Neuroradiology. 2018;60:437-446

Author contact

Corresponding author: Giovanni Morana, MD, PhD, Neuroradiology Unit, IRCCS Istituto Giannina Gaslini, via G. Gaslini 5 16147 Genova, Italy. Tel. (39) 010 56362516; Fax (39) 010 3779798; E-mail: giovanni.moranait; Orcid ID: http://orcid.org/0000-0001-8707-5969.

Received 2020-7-12
Accepted 2020-10-3
Published 2020-10-25

Citation styles

©2024 Ivyspring International Publisher. Terms of use